Standard recommendations for the management of psoriatic arthritis
J. Štolfa; K. Pavelka; J. Vencovský
Revmatologický ústav Praha
Čes. Revmatol., 13, 2005, No. 3, p. 97-105.
Psoriatic arthritis (PsA) is a chronic inflammatory joint disorder characterized by arthritis and psoriasis. Potential treatment of psoriatic arthritis, in contrast to rheumatoid arthritis, is limited and includes sulphasalazine, methotrexate, and cyclosporine A. Biologic treatment represents a new promise. Infliximab and etanercept are currently registered for the treatment of psoriatic arthritis. Adalimumab registration is being awaited. There are no standard recommendations for the “conventional” as well as biological management for the treatment of psoriatic arthritis in the Czech specialized journals. The idea of this paper is to complete this missing link. The summary of “conventional” pharmaceutical therapy for psoriatic arthritis and strategy of its administration is described here. Furthermore, biologic agents registered and used in the Czech Republic as well as agents that are in the development are described. Finally, standard recommendations for the biologic management for psoriatic arthritis are presented. Czech rheumatology association reviewed and endorsed these recommendations.
psoriatic arthritis, pharmacotherapy of psoriatic arthritis, biologic management of psoriatic arthritis, standard recommendations for the management of psoriatic arthritis
Dermatology & STDs